Identification of a small molecule that compromises the structural integrity of viroplasms and rotavirus double-layered particles

Eichwald, Catherine; De Lorenzo, Giuditta; Schraner, Elisabeth M; Papa, Guido; Bollati, Michela; Swuec, Paolo; de Rosa, Matteo; Milani, Mario; Mastrangelo, Eloise; Ackermann, Mathias; Burrone, Oscar R; Arnoldi, Francesca

Abstract: Despite the availability of two attenuated vaccines, rotavirus (RV) gastroenteritis remains an important cause of mortality among children in developing countries causing about 215,000 infant deaths annually. Currently, there are no specific antiviral therapies available. RV is a non-enveloped virus with a segmented double-stranded RNA genome. Viral genome replication and assembly of transcriptionally active double-layered particles (DLPs) take place in cytoplasmic viral structures called viroplasms. In this study, we describe strong impairment of the early stages of RV replication induced by a small molecule known as RNA polymerase III inhibitor, ML-60218 (ML). This compound was found to disrupt already assembled viroplasms and hamper the formation of new ones without the need of de novo transcription of cellular RNAs. This phenotype correlated with reduction in accumulated viral proteins and newly made viral genome segments, disappearance of the hyperphosphorylated isoforms of the viroplasm-resident protein NSP5 and inhibition of infectious progeny virus production. In in vitro transcription assays with purified DLPs, ML showed a dose-dependent inhibitory activity indicating the viral nature of its target. ML was found to interfere with the formation of higher order structures of VP6, the protein forming the DLP outer layer, without compromising its ability to trimerize. Electron microscopy of ML-treated DLPs showed a dose-dependent structural damage. Our data suggest that interactions between VP6 trimers are essential not only for DLP stability but also for the structural integrity of viroplasms in infected cells.

IMPORTANTANCE Rotavirus gastroenteritis is responsible for a large number of infant deaths in developing countries. Unfortunately, in those countries where effective vaccines are urgently needed, the efficacy of the available vaccines is particularly low. Therefore, the development of antivirals is an important goal, as they might complement the available vaccines or represent an alternative option. Moreover, they may be decisive in fighting the acute phase of infection. This work describes the inhibitory effect on rotavirus replication of a small molecule initially reported as an RNA polymerase III inhibitor. The molecule is the first chemical compound identified able to disrupt viroplasms, the viral replication machinery, and to compromise the stability of DLPs by targeting the viral protein VP6. This molecule thus represents a starting point towards the development of more potent and less cytotoxic compounds against rotavirus infection.

DOI: https://doi.org/10.1128/JVI.01943-17

Accepted Version
Identification of a small molecule that compromises the structural integrity of viroplasms and rotavirus double-layered particles

Catherine Eichwald\textsuperscript{a}, Giuditta De Lorenzo\textsuperscript{b,*}, Elisabeth M. Schraner\textsuperscript{a}, Guido Papa\textsuperscript{b}, Michela Bollati\textsuperscript{c}, Paolo Swuec\textsuperscript{d}, Matteo de Rosa\textsuperscript{c}, Mario Milani\textsuperscript{c}, Eloise Mastrangelo\textsuperscript{c}, Mathias Ackermann\textsuperscript{a}, Oscar R. Burrone\textsuperscript{b}, and Francesca Arnoldi\textsuperscript{b,e,#}

Institute of Virology, University of Zürich, Zürich, Switzerland\textsuperscript{a}; International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy\textsuperscript{b}; Biophysics Institute of the National Research Council (CNR-IBF), Department of Biosciences, University of Milan, Milan, Italy\textsuperscript{c}; Pediatric Clinical Research Center Fondazione Romeo ed Enrica Invernizzi, Department of Biosciences, University of Milan, Milan, Italy\textsuperscript{d}; Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy\textsuperscript{e}

Running Head: A chemical inhibitor of rotavirus replication

# Address correspondence to Francesca Arnoldi, farnoldi@units.it

*Present address: Giuditta De Lorenzo, MRC – University of Glasgow Centre for Virus Research, Glasgow, UK

Word counts for abstract and text are 234 and 6,080, respectively
ABSTRACT

Despite the availability of two attenuated vaccines, rotavirus (RV) gastroenteritis remains an important cause of mortality among children in developing countries causing about 215,000 infant deaths annually. Currently, there are no specific antiviral therapies available. RV is a non-enveloped virus with a segmented double-stranded RNA genome. Viral genome replication and assembly of transcriptionally active double-layered particles (DLPs) take place in cytoplasmic viral structures called viroplasms. In this study, we describe strong impairment of the early stages of RV replication induced by a small molecule known as RNA polymerase III inhibitor, ML-60218 (ML). This compound was found to disrupt already assembled viroplasms and hamper the formation of new ones without the need of de novo transcription of cellular RNAs. This phenotype correlated with reduction in accumulated viral proteins and newly made viral genome segments, disappearance of the hyperphosphorylated isoforms of the viroplasm-resident protein NSP5 and inhibition of infectious progeny virus production. In in vitro transcription assays with purified DLPs, ML showed a dose-dependent inhibitory activity indicating the viral nature of its target. ML was found to interfere with the formation of higher order structures of VP6, the protein forming the DLP outer layer, without compromising its ability to trimerize. Electron microscopy of ML-treated DLPs showed a dose-dependent structural damage. Our data suggest that interactions between VP6 trimers are essential not only for DLP stability but also for the structural integrity of viroplasms in infected cells.

IMPORTANCE

Rotavirus gastroenteritis is responsible for a large number of infant deaths in developing countries. Unfortunately, in those countries where effective vaccines are urgently
needed, the efficacy of the available vaccines is particularly low. Therefore, the development of antivirals is an important goal, as they might complement the available vaccines or represent an alternative option. Moreover, they may be decisive in fighting the acute phase of infection. This work describes the inhibitory effect on rotavirus replication of a small molecule initially reported as an RNA polymerase III inhibitor. The molecule is the first chemical compound identified able to disrupt viroplasms, the viral replication machinery, and to compromise the stability of DLPs by targeting the viral protein VP6. This molecule thus represents a starting point towards the development of more potent and less cytotoxic compounds against rotavirus infection.

**INTRODUCTION**

Rotavirus (RV) is the most common cause of gastroenteritis in young children and infants throughout the world. The impact of RV vaccines on global estimates of RV mortality has been limited, and the rate of deaths due to RV gastroenteritis in developing countries is still approximately between 197,000–233,000 per year (1). Currently, there are no specific antivirals available. The virus belongs to the *Reoviridae* family, is non-enveloped and contains a genome of eleven segments of double-stranded RNA. During entry into the host cell (enterocytes of the intestinal villi), the virion (triple-layered particle, TLP) loses the outer of its three concentric protein layers formed by the glycoprotein VP7 and the spike protein VP4 and becomes a transcriptionally active double-layered particle (DLP). The viral RNA-dependent RNA polymerase VP1 acts both as transcriptase (synthesis of viral mRNAs) and as replicase (synthesis of minus strands resulting in new genome segments) (2). To be transcriptionally active, VP1 must be localized within a DLP. Both DLP layers, the inner one formed by VP2 and the outer one formed by VP6 trimers, are required to guarantee transcriptional activity.
Removal of VP6 from DLPs abolishes this activity, which can be recovered by adding native or recombinant VP6 (3, 4). The transcribed plus-stranded RNAs act as both messengers for viral protein synthesis and templates for viral genome replication. The viral genome is replicated in viral cytoplasmic structures called viroplasms, where also the assembly of progeny DLPs takes place. These newly synthesized DLPs perform a second round of transcription, called secondary transcription, which produces additional plus-stranded RNAs (5, 6). In the final stages of virus morphogenesis, the progeny DLPs bud into the ER acquiring a transient envelope, which is then replaced by the viral proteins (VP7, VP4) forming the outer layer of progeny TLPs (2).

In addition to the structural proteins forming DLPs (VP1, the capping enzyme VP3, VP2, and VP6), two viral non-structural proteins are also found in viroplasms: NSP5 and NSP2. Both are essential for viroplasm formation and therefore for viral replication (6-9). During viral infection, NSP5 undergoes a complex hyperphosphorylation process involving different kinases and interactions with other viral proteins (10-12). However, the role of this post-translational modification in the viral replication cycle is not completely understood. In fact, several lines of evidence show correlation between viroplasm formation and NSP5 phosphorylation (13-15). Also, NSP2 and VP2 were recently found phosphorylated, and it has been proposed that viroplasm formation is a phosphorylation-dependent process (11).

The number and size of viroplasms in infected cells are indicative of viral replication efficiency. These values decrease in the presence of compounds with antiviral effect on the early steps of the viral cycle, like inhibitors of proteasome (16), microtubules (MT) (17), Eg5 kinesin (17) and thiazolides (18), that interfere with viroplasm assembly and virus infectivity. Ribavirin has also been reported to affect RV replication (19). In this work, we describe the unexpected antiviral activity of a chemical compound, ML-60218 (referred to as ML), reported...
as an inhibitor of the RNA polymerase III complex (20). The effect on RV shown here is independent of the RNA polymerase III catalytic activity. For the first time, we describe a chemical compound able to disrupt viroplasms in virus-infected cells and compromise the stability of purified DLPs by interfering with interactions between VP6 trimers.

RESULTS

ML impairs viroplasm formation and disrupts already assembled viroplasms. Treatment of RV-infected cells with ML at 10 μM caused a strong reduction of viroplasms accumulated during viral replication and, in the case of the porcine OSU strain, a complete disappearance of those structures, as observed by both immunofluorescence (Fig. 1) and electron microscopy analysis (Fig. 2). Independently of whether the compound was added at 1, 3 or 5 hours post-infection (hpi), a 4 h treatment had the same effect on viroplasms (Fig. 1A). Viroplasm disruption correlated with a decrease of accumulated viral proteins, as observed with the porcine OSU and the simian SA11 strains (Fig. 1B). When added before infection, together with the infectious virion, or at 1 hpi (Fig. 1C, upper panel), ML caused a reduction of viral proteins in a dose-dependent manner with a concomitant disappearance of the NSP5 hyperphosphorylated isoforms (Fig. 1C, middle panel). ML added at the concentration of 10 μM together with the infectious virions completely blocked assembly of viroplasms (Fig. 1C, bottom panel). The same phenotype was observed in two different cell lines (monkey kidney epithelial MA104 cells and human osteosarcoma U2OS cells) upon infection with two different RV strains (OSU and SA11) (Fig. 1D and E).

The absence of viroplasms and the reduction of accumulated viral proteins indicate that ML inhibits RV replication. This result was confirmed assessing the yield of infectious progeny virus produced at different time points post-infection (Fig. 1F) and the production of
newly made dsRNA genome segments (gs) (Fig. 1G). During the time intervals of the analysis, ML was not cytotoxic (Fig. 1H).

Three hours was the minimum time and 10 μM the minimal concentration required for complete effect on viroplasms (data not shown). Concentrations higher than 20 μM were toxic for cells, as shown by the decreased levels of actin in Western blots (Fig. 1C). Treatments of up to 12-14 h at 10 μM were well tolerated (Fig. 1H).

**ML-mediated viroplasm disruption causes NSP5 dephosphorylation.** In order to determine whether the effect of ML on NSP5 phosphorylation was due to activation of phosphatases, 0.5 μM okadaic acid (an inhibitor of serine/threonine phosphatases) was added to OSU-infected cells at 3 hpi (1 h before the addition of ML), and maintained during the following 4 h treatment (see scheme in Fig. 3). Upon inhibition of phosphatases with okadaic acid, the effect of ML on viroplasms remained unaltered (Fig. 3, bottom right panel) but NSP5 hyperphosphorylated isoforms did not disappear (Fig. 3, lane 2). This result suggests that the effect of ML on viroplasms is not mediated by activation of phosphatases and that NSP5 dephosphorylation is the consequence of disruption of viroplasms which, when intact, protect NSP5 from cytosolic phosphatases.

**ML activity against RV does not require newly synthesized cellular transcripts or proteins and is independent of the RNA polymerase III catalytic activity.** To determine whether the phenotype observed under ML treatment was due to de novo synthesis of cellular proteins or RNAs, actinomycin D was added to cells at 3 h post-infection, one hour before treatment with the drug, and maintained during the following 4 h treatment (see scheme in Fig. 4A). Actinomycin D is a DNA intercalator that inhibits transcription of RNA polymerase I at very low concentrations (>0.01 μg/ml), of RNA polymerase II at concentrations higher than 2 μg/ml, and of RNA polymerase III at concentrations higher than 5 μg/ml (21, 22). Newly
synthesized RNAs were labeled with the ribonucleoside homolog 5-ethynyl uridine (EU) and visualized by reacting with an Alexa-488 conjugated azide (green) (Fig. 4A, right panel) to assess the effectiveness of actinomycin D treatment. Actinomycin D at 10 μg/ml did not interfere with the effect of ML indicating that newly synthesized cellular transcripts are not required for ML antiviral activity. Also, in the absence of ML, treatment with actinomycin D did not compromise viroplasm integrity nor affected the accumulation of viral proteins (Fig. 4A, left panel). On the contrary, it slightly increased the amounts of VP2 and NSP5 compared to the untreated control (Fig. 4A, lane 2 vs. lane 1). This result explains why actinomycin D was found to compensate the decrease of VP2 induced by ML (Fig. 4A, left panel, lane 4 vs. lane 3). All these data indicate that RV replication does not require the catalytic activity of RNA polymerase III and that ML activity against RV is not mediated by inhibition of this cellular target. In addition, de novo protein synthesis is not required for ML activity. Addition of ML (at 4 hpi) to cells treated with the protein synthesis inhibitor cycloheximide (CHX) (added at 3 hpi) still caused viroplasm disruption and NSP5 dephosphorylation (Fig. 4B).

**ML compromises DLPs stability.** We then investigated whether ML acts on a viral target. RV DLPs were purified from cells infected with OSU or SA11 strains, and their transcriptional activity tested in vitro in the presence of increasing ML concentrations. An irrelevant small molecule (compound #7749832, ChemBridge Corp.) solubilized in the same buffer was used as a control. Upon incubation with ML, the number of transcripts produced by DLPs of both strains was significantly decreased in a dose-dependent manner (Fig. 5A) as compared to the vehicle or the irrelevant small molecule. An IC$_{50}$ of 10 μM was observed for both viruses. In order to be transcriptionally active, DLPs must be intact. The sole absence of the external layer formed by VP6 trimers is sufficient to compromise the transcriptional activity (3, 4, 21). Interestingly, electron microscopy (EM) analyses on purified DLPs showed that 4 h incubation
with ML (in the same buffer used for the *in vitro* transcription assays) caused structural damage in a dose-dependent manner. DLPs with an irregular shape and partially open were observed (Fig. 5B). Quantifications in all samples are plotted in Fig. 5C. Altogether these results suggest that ML compromises the structural integrity of DLPs, thus impairing their transcriptional activity.

**ML interferes with higher order VP6 structures.** Although ML clearly altered DLP morphology, the EM images showed the presence of residual structures (Fig. 5, white arrows). These structures could be DLPs partially or totally deprived of the VP6 layer. We thus investigated whether ML impaired the interaction of VP6 with VP2 or with itself, as in the formation of trimers or in the interactions between trimers.

The VP6-VP2 interaction was tested by co-immunoprecipitation with an anti-VP6 monoclonal antibody (clone RV-138) from cells overexpressing both VP6 and VP2 and treated for 5 h with ML. The inhibitor was also maintained during cell lysis and incubation with the precipitating antibody. The experiment, repeated at various ML concentrations (up to the highest concentration used of 200 μM), showed that ML did not interfere with VP6-VP2 interactions (Fig. 6A).

VP6 trimer formation was assessed by Western blots of non-boiled lysates from cells overexpressing VP6 and treated with ML. In fact, VP6 trimers (MW = 135 kDa) resist SDS denaturing and reducing conditions but not high temperatures (23). Cells infected with a recombinant vaccinia virus expressing VP6 (vvVP6) were treated with ML at 1 hpi for 7 h. VP6 trimers formed *in vivo* were not affected by the presence of ML (Fig. 6B, left panel), which did not compromise the total levels of VP6 expression. Intact VP6 trimers were also found in RV-infected cells treated with ML, although in decreased amounts because of the reduced viral replication (Fig. 6B, right panel). ML, however, appears to interfere with the
formation of VP6 higher order structures typically observed in cells overexpressing VP6 in the absence of other RV proteins (24) (Fig. 6C). In immunofluorescence, VP6 staining showed tubular structures or aggregates, while in the presence of ML it showed homogenous distribution (Fig. 6C). In contrast, other structures such as viroplasm-like structures (VLS) generated by overexpression of NSP5 with NSP2 (VLS-NSP2) or with VP2 (VLS-VP2) (24, 25) or with both, were not affected by ML treatment (Fig. 7A, C). Under these conditions, NSP5 remained hyperphosphorylated and VP6 recruitment into VLS was not compromised (Fig. 7B-C).

Depending on pH and ionic strength, purified VP6 self-assembles into helical tubes or spherical particles ((26) and Fig. 6D, left panels). Two different types of tubes can be reconstituted in vitro, characterized by a constant diameter of either 45 or 75 nm with a non-fixed length of several μm. On the other hand, VP6 spheres are heterogeneous in size with diameters varying from 75 to 100 nm (26, 27). In order to evaluate whether ML had an effect on the assembly of these VP6 structures, we performed a negative staining electron microscopy analysis on purified VP6 in the presence or absence of ML. Upon incubation with 25 µM ML, both VP6 tubes (pH 6.0) and spherical particles (pH 4.0) were severely damaged (Fig. 6D). In fact, a thorough visual inspection of the EM grids failed to reveal any intact tube or sphere in the presence of ML (Fig. 6D, right panels). Thus, ML has a direct effect on the higher order interactions of VP6 trimers.

To further study the effect of ML on VP6, the interaction between the protein and the drug was evaluated in nanoscale thermophoresis assays. Upon addition of the inhibitor, a concentration-dependent quenching of the labeled protein was observed, which allowed us to calculate an EC₅₀ value of 294 ± 62 µM (Fig. 6E). Since millimolar concentrations of divalent cations are known to destabilize the VP6 higher order structures shifting the equilibrium...
toward isolated trimers (26), thermophoresis mobility was also tested in the presence of CaCl$_2$ (up to 500 mM). No significant changes were observed (data not shown). Thus, in the thermophoresis experimental conditions, the signal observed was due to direct binding of ML to VP6 trimers, rather than to a destabilization of its oligomerization state. Altogether, these results suggest that, although ML binds VP6 trimers with moderate affinity, it likely prevents the optimal packing of its higher oligomeric structures on the DLP outer layer. Whether this is due to a conformational change induced by the molecule or to a steric hindrance effect is not known and awaits structural confirmation.

The effect of ML on viroplasms and VP6 strongly indicates that VP6 plays an essential role in the structural integrity of viroplasms. In fact, as already reported (5), silencing VP6 expression with a specific siRNA led to a significant reduction of viroplasm number in RV-infected cells (Fig. 8A), strengthening the hypothesis that VP6 is essential for maintaining the structure of viroplasms. Of note, in ML-treated virus-infected cells VP6 was found diffused throughout the cytosol (Fig. 8B).

**DISCUSSION**

We describe for the first time a compound able to disrupt already formed RV viroplasms in infected cells, thus impairing RV replication as demonstrated by the decrease in viral protein translation, *de novo* synthesis of viral genomic dsRNA and yield of progeny virus. This effect of ML on RV replication was initially surprising because this drug, a cell-permeating indazole-sulfonamide small molecule, has been described to favor replication of some DNA viruses and bacteria by inhibiting the RNA polymerase III-mediated mechanism that activates the RIG-I pathway (28-30). RV, however, is an RNA virus. We ruled out that ML inhibition was mediated by RNA polymerase III activity as actinomycin D, used at a
concentration that inhibits RNA polymerase III transcription, still allowed RV replication. In addition, actinomycin D was unable to counteract the ML antiviral effect, indicating that ML antiviral activity does not require synthesis of newly made cellular transcripts, including those of RNA polymerase III. This is consistent with the finding that the ML target is of viral nature. We showed that ML impaired DLP stability in vitro by inhibiting the interactions between VP6 trimers. In the absence of a correctly assembled VP6 layer, DLPs lose the capacity to transcribe plus-stranded RNAs (3, 31). These results explain the decreased amount of transcripts obtained in vitro from purified DLPs and provide the basis for the reduced amounts of viral proteins and dsRNAs observed in infected cells treated with ML. Altogether these data indicate that the inhibitor binds VP6, compromising both the integrity of DLPs and the structure of viroplasms.

The mechanism of viroplasm assembly is still not well understood. Viroplasms contain six viral proteins: two non-structural, NSP5 and NSP2 (both shown to be essentially required for viroplasm formation (6, 7, 32)), and four structural proteins, VP1, VP2, VP3 and VP6 (33). Electron microscopy studies suggested that newly made DLPs assemble at the periphery of viroplasms (34). Immunogold labeling of VP6 indicated that this protein localizes exclusively at the periphery of viroplasms, while NSP5, NSP2, and VP2 were also detected in the viroplasm interior (Arnoldi et al., unpublished results). Silencing VP6 expression leads to fewer and smaller viroplasms and reduced amounts of viral mRNAs, viral dsRNAs and viral proteins (5), indicating that this protein is also required for the structural and functional integrity of viroplasms. We confirmed that knocking down VP6 expression produced a sharp reduction in the number of viroplasms (Fig. 8 and (5)), consistently with the capacity of ML to hamper viroplasms by interaction with VP6. However, it is not clear whether the destabilizing
effect on viroplasm structure is the consequence of damaging the VP6 layer in newly assembled DLPs or impairing VP6 interactions outside the context of DLPs.

Disruption of already assembled viroplasms was particularly evident with OSU and less pronounced with SA11, suggesting that viroplasms may have different stability depending on the strain. The decrease of accumulated viral proteins was nevertheless comparable with the two strains and suggests that ML targets a structural region of VP6 that is conserved among different viruses.

Noteworthy, ML did not interfere with formation of VLS nor with recruitment of VP6 into VLS, suggesting that: i) ML does not target the interactions required for VLS assembly (NSP5 with either NSP2 or VP2) or for recruitment of VP6 into VLS, that depends on its interaction with VP2 (24); ii) VLS are clearly different from viroplasms, as previously reported (16). The lack of ML effect on VP2-VP6 interaction was further confirmed by the co-immunoprecipitation experiments.

Interestingly, a strong reduction of NSP5 hyperphosphorylation was observed upon treatment with ML. NSP5 hyperphosphorylation has been associated to RV replication because of its link with viroplasm formation: i) the two events have been found correlated during the course of viral infection (15); ii) overexpression of NSP5 with either NSP2 or VP2 in uninfected cells induces both NSP5 hyperphosphorylation and VLS formation (13, 24, 25, 35); iii) silencing of casein kinase 1-alpha that affects NSP5 phosphorylation (but does not abolish it entirely) produces viroplasms with irregular shapes (14). Recently, it was shown that at the beginning of infection hypophosphorylated NSP5 interacts with a cytoplasmically dispersed form of NSP2 and was then proposed that during infection phosphorylation of not only NSP5, but also of NSP2, and possibly of VP2, leads to viroplasm maturation (11). Our data in cells treated with both ML and the phosphatase inhibitor okadaic acid show for the first time that
NSP5 can remain hyperphosphorylated in infected cells in the absence of viroplasms. Such finding indicates that viroplasms protect NSP5 from dephosphorylation. This result in part supports the model suggested by Criglar et al. (11) that proposes an initial interaction among non- or hypophosphorylated viral proteins. However, although a mechanism of concerted phosphorylation involving several proteins of viroplasms might be necessary for subsequent viroplasm maturation and functioning, our data suggest that NSP5 hyperphosphorylation is necessary but not sufficient for viroplasm formation. In this regard, treatment of uninfected cells expressing recombinant NSP5 with inhibitors of cellular phosphatases leads to NSP5 hyperphosphorylation, but not to VLS formation (36).

So far, a few types of molecules such as proteasome inhibitors (MG132, Bortezomib) (16), MT-depolymerizing drugs (nocodazole, vinblastine) (17), an allosteric inhibitor of Eg5 kinesin (monastrol) (17) and thiazolides (18) were shown to affect RV viroplasms. Proteasome inhibitors impair the formation of new viroplasms without affecting the stability of those already assembled, do not show any inhibitory activity on RV particles in vitro and do not interfere with the formation of VLS in transfected cells. Although the inhibition mechanism remains obscure, it was hypothesized that the effect was the consequence of blocking proteasome-mediated degradation of an unknown host factor capable of impairing formation of viroplasms (16, 37). Regarding MT-depolymerizing drugs and Eg5 kinesin inhibitor, they both destabilize the viroplasm structure and their coalescence but do not reduce viral proteins expression (17). Finally, treatment with thiazolides causes a reduction in the viroplasm size, resulting in an inhibition of the dsRNA genome segments synthesis, but without impairing viral protein expression or affecting stability of RV particles (18). Importantly, the compound described in this work is the only RV inhibitor so far identified that can disrupt viroplasms and acts on a viral target. This makes the chemical structure of ML particularly appealing for
further studies in the field of antivirals. As such, ML could not be used as an antiviral drug, because of its cytotoxicity. However, future research and structural analyses might lead to the development of more potent and selective inhibitors as potential drugs against RV infections.

**MATERIALS AND METHODS**

**Cells and viruses.** MA104 cells (embryonic African green monkey kidney cells, ATCC® CRL-2378) were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (Life Technologies) containing 10% Fetal Bovine Serum (Life Technologies), and 50 μg/ml gentamycin (Biochrom AG). BSC-40 cells (green monkey kidney epithelial cells, ATCC® CRL-2761) were cultured in DMEM supplemented with 10% fetal calf serum (AMIMED, Switzerland) and penicillin (100 units/ml)-streptomycin (0.1 mg/ml) (Sigma). Sf9 cells (*Spodoptera frugiperda* ovary cells, ATCC® CRL-1711™) were grown in suspension in Sf-900™ II SFM medium (Thermo Fisher Scientific) at 27°C.

For RV-infection experiments, the porcine OSU (G5, P9[7]) and simian SA11 4F (G3, P6[1]) strains of RV were used; they were propagated in MA104 cells as described previously (38, 39). Virus titers were determined as described by Eichwald *et al.* (17) and expressed as “viroplasm forming units” (VFU/ml). Purified DLPs were obtained by CsCl gradient purification from infected MA104 cells, essentially as described by Patton *et al.*, 2000 (40).

For experiments of VLS production and VP6 overexpression in uninfected cells, MA104 cells were infected, respectively, with a T7 RNA polymerase recombinant vaccinia virus (strain vvTF7.3) (41), and vvT7/LacO1/VP6 virus (vvVP6), an IPTG-inducible recombinant vaccinia virus driving expression of both the T7 RNA polymerase and VP6 under induction with 1mM IPTG. For generation of vvVP6, BSC-40 cells were infected with recombinant vaccinia virus vvT7/LacO1 (42) and transfected with pVOTE.1-VP6. Selection and
amplification were carried out as described by Earl and Moss (43). The plasmid pVOTE.1 and vvT7/LacOI were kindly provided by B. Moss.

For the heterologous production of VP6 protein, the recombinant baculovirus BacVP6C (44) was kindly provided by D. Poncet.

**Chemicals.** Cells were treated with ML (from 5 to 20 μM, Merck Millipore) following the kinetic indicated in the Results section. Actinomycin D (0.1 μg/ml, Sigma), okadaic acid (0.5 μM, Sigma), and cycloheximide (0.1 μg/ml, Sigma) were added to cells from 3 to 8 hours post-infection (hpi). Purified DLPs were treated with ML (from 2.5 to 200 μM, as indicated in the Results section) or with 200 μM of irrelevant compound (ID #7749832, ChemBridge Corp).

**Plasmid constructions.** The plasmids pcDNA3-NSP5, -NSP2, -VP6 and -VP2 used to overexpress RV proteins in uninfected cells were already described previously (13, 35, 45). The plasmid pVOTE.1-VP6 was obtained by PCR amplification of VP6 mouse EC strain, using specific primers (5'-ATGCCCATGGATGTGCTGTACTCCATC-3' and 5'-GATCGGATCCTCACTT TACCAGCATGCTTCTTCCATC-3') to incorporate NcoI and BamHI restriction sites at the 5' and 3' ends, respectively. The amplified fragment was ligated between NcoI and BamHI restriction sites in pVOTE.1 (42). All primer sequences used in this study for PCR and sequencing are available upon request to the authors.

**Infections and transient transfections.** Infection experiments with RV were carried out at an MOI of 25 VFU/cell (17). For overexpression of RV proteins in uninfected cells, confluent monolayers of MA104 cells in 12-well plates were infected with vvTF7.3 at an MOI of 10 pfu/cell (41, 46). At 1 hpi, cells were transfected with a total of 2 μg of DNA plasmid using Lipofectamine 3000 (ThermoFisher Scientific) according to the manufacturer’s instructions. At 16 hpi, cells were washed once to remove serum and then treated with 10 μM ML in serum-free DMEM medium for 5 hours. Cells were then collected for immunofluorescence or
Western blot analyses. For VP6 overexpression, confluent monolayers of MA104 cells in 12-well plates were infected with vvVP6 (MOI; 10 pfu/cell). At 1 hpi, both 1mM IPTG and 10 μM ML were added, and 7 h later cells were collected for immunofluorescence or Western blot analyses.

For experiments with siRNAs against VP6 (siVP6-OSU: UGGAACAUCAUAGCUAGAAA; siVP6-SA11: UGGAACAUACGUAGCUAGAAA), 5x10⁴ MA104 cells per well were seeded into 12-well plates and the next day transfected with 0.1 nmol of annealed duplex siRNA (Sigma) using 5 μl of RNAiMAX Lipofectamine 2000 (ThermoFisher Scientific) according to the manufacturer’s instructions. Control siRNAs were siNSP5-SA11 and siNSP5-OSU here referred as siNT and described by Campagna et al., 2005 (7). At 48 hpt cells were infected at the same MOI and collected at 6 hpi (for viroplasm counting by immunofluorescence or Western blot analyses).

Cellular extracts (about 3 x 10⁵ cells) were prepared with 50 μl of reducing SDS buffer (125 mM Tris-HCl pH 6.8, 6% SDS, 40% glycerol, 5% β-mercaptoethanol, 0.04% bromophenol blue) and subsequently sonicated with a VialTweeter (Hielscher Ultrasonics GmbH) for 1 min (10 W, pulse 0.5 sec) to disrupt DNA. Typically, 10 μl of cellular extracts were loaded onto an SDS-polyacrylamide gel for Western blot analyses. For VP6 trimer analyses, cellular extracts were prepared in TNN lysis buffer (100 mM Tris-HCl, pH 8, 250 mM NaCl, 0.5% NP-40 and 30 mM N-ethylmaleimide) and centrifuged at 5,000 x g for 5 min at 4˚C. For immunoprecipitation assays, cellular extracts were prepared in radioimmunoprecipitation assay (RIPA) buffer (10 mM Tris-HCl, 1% Triton X-100, 0.5% sodium deoxycholate, 1 mM EDTA, 150 mM NaCl [pH 7.4]), incubated on ice for 15 min, and then centrifuged at 13,000 x g for 5 min at 4˚C.
Immunoprecipitation and protein analysis. For immunoprecipitation assays, usually 4/5 of the total extract, i.e. approximately 80 μl, were immunoprecipitated for 2h at 4°C after addition of 100 μl of an undiluted mouse anti-VP6 (clone RV138) monoclonal antibody supernatant (47) (kindly provided by D. Agnello and P. Pothier), 1 μl of a Protease Inhibitor Cocktail (Sigma), and 50 μl of 50% immobilised rProtein A beads (Repligen Bioprocessing) in RIPA buffer. Beads were washed four times with RIPA buffer, followed by one wash with PBS and resuspended in 20 μl of loading buffer. Proteins were separated by SDS-polyacrylamide gel and transferred to polyvinylidene difluoride membranes (Millipore, IPVH00010) (48). For protein analysis of either cellular extracts or immunoprecipitated proteins, membranes were incubated with the following primary antibodies: anti-NSP5 (1:10,000) (46), anti-VP2 (1:5,000) (35), anti-RV (1:2,500) (17), anti-VP1 (1:5,000) (35) guinea pig sera, anti-NSP3 rabbit serum (1:1,500) (kindly provided by S. López), anti-NSP4 rabbit serum (1:1,100) (kindly provided by D. Luque), anti-VP5 clone 2G4 mouse monoclonal antibody (1:2,000) (kindly provided by H. Greenberg), anti-alpha-tubulin mouse monoclonal antibody (1:3,000, Calbiochem), anti-actin rabbit polyclonal antibody (1:1,000, Sigma). The membranes were then incubated with the corresponding HRP-conjugated goat anti-guinea pig (1:10,000, Jackson ImmunoResearch), goat anti-mouse (1:5,000, Jackson ImmunoResearch), goat anti-rabbit (1:5,000, Thermo Scientific Pierce) secondary antibodies. Signals were detected by using the enhanced chemiluminescence system (Pierce ECL Western Blotting Substrate, Thermo Scientific).

Immunofluorescence microscopy. Immunofluorescence experiments were performed as described previously (49) using the following antibody dilutions: anti-NSP5 guinea pig serum 1:1,000; anti-VP6 mouse monoclonal antibody (clone 4B2D2) 1:1,000 (kindly provided by J. L. Zambrano and F. Liprandi); Alexa Fluor® 488-conjugated anti-mouse (1:500, Life
Technologies) and Alexa Fluor® 546-conjugated anti-rabbit (1:500, Life Technologies) secondary antibodies. Newly synthesized RNAs were labeled using 2 mM ethylene uridine (EU) ribonucleotide homolog containing an alkyne reactive group, and the modified incorporated nucleotide was revealed with an azide-containing fluorophore (Alexa-488, green), as described for Click-iT® RNA Alexa Fluor® 488 Imaging Kit (Thermo Fisher Scientific). Cell nuclei were stained with 2 μg/ml Hoechst 33342 (Molecular Probes, Life Technologies). Samples were analyzed by confocal microscopy (Zeiss LSM510 equipped with a 100x NA 1.3 objective), and images were processed using LSM Image Examiner 4.0 Software.

Analysis of RV genome segments. Total RNA was purified from MA104 cells infected with OSU (MOI; 25 VFU/cell) after treatment with 10 μM ML or a control vehicle (dimethyl sulfoxide, DMSO) from 1 to 6 hpi. Crude viral preparations were digested with 10 μg/ml of proteinase K (Thermo Fisher Scientific) in the presence of 5 mM EDTA and 0.5% SDS, for 30 min at 60°C. RNA was then purified by phenol-chloroform extraction and precipitation with 5M ammonium acetate and quantified using the NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific). 3.5 μg of total RNA were separated by Tris-glycine nondenaturing polyacrylamide (4% stacking gel, 10% resolving gel) and transferred to a charged nylon membrane (GeneScreen Plus Hybridization Transfer Membrane, Perkin Elmer). The membrane was blocked with 5% milk and 50 μg/ml DNA fish sperm (Affymetrix) in PBS and was incubated overnight with the mouse anti-dsRNA (clone J2) monoclonal antibody (1:1,000; English and Scientific Consulting Bt., Hungary) (50), followed by reaction with HRP-conjugated goat anti-mouse antibody (1:5,000, Jackson ImmunoResearch).

Cell viability assay. 2x10^5 MA104 cells were seeded in 12-well plates. After infection and drug treatment for the indicated time points, supernatants were removed and stored and cells...
were trypsinized (0.5% trypsin-EDTA, Gibco, ThermoFisher Scientific) and then mixed with supernatants in order not to lose suffering cells possibly detached. After centrifugation at 900 x g for 2 min at room temperature (RT), pellets were resuspended in 200 µl of 0.5 ng/µl propidium iodide in PBS and incubated in the dark for 15 min at RT. Samples were diluted to 1 ml with PBS, filtered using a cell strained snap-cap tube (BD Falcon™) and immediately acquired in a Gallios™ Flow Cytometer (Beckman Coulter, Inc.). For this purpose, 10,000 events were acquired, exciting at 488 nm with an argon laser and a filter band of 675/20 BP. Data were analyzed gating on live cells using a Kaluza® Flow Analysis Software. The statistical analysis and plot were performed using Microsoft® Excel® for MAC 2011 Version 14.7.0.

**Determination of progeny virus yield.** 2x10^5 MA104 cells seeded in 12-well plates were RV-infected with an MOI of 25 VFU/cell. Virus adsorption was performed for 1 h at 4°C, followed by incubation at 37°C. At 2 hpi, cells were washed twice with PBS and 10µM ML or vehicle (2% DMSO) diluted in 500µl DMEM was added. At the indicated time points, plates were frozen at -80°C. Cells were then treated with three freeze-thaw cycles, harvested and centrifuged at 17,000 x g for 5 min at 4°C. The supernatant was recovered and activated with 80µg/ml of trypsin for 30 min at 37°C. Serial dilutions were prepared and used to determine the viral titers as described by Eichwald et al., 2012 (17).

**In vitro transcription assays with purified DLPs.** 1 µg of purified DLPs were incubated for 4 h at 42°C in a total volume of 100 µl of 1X T7 transcription buffer from Promega, 2mM of each NTP, 0.5 mM SAM, 0.1 mM MnCl₂, 1mM DTT, 0.4 U RNAsin® (Promega). RNA was isolated using the GeneJET RNA Cleanup and concentration Micro kit (Thermo Fisher Scientific) and quantified using the Qubit RNA Assay Kits associated to a Qubit 2.0
Fluorometer (Thermo Fisher Scientific). The statistical analyses were performed using Student’s t-Test by comparing vehicle and ML-treated particles of each viral strain.

Production of recombinant Baculovirus VP6. A Sf9 suspension culture (1 x 10^6 cells/ml) was infected with recombinant baculovirus BacVP6C (27). At 3 days post-infection, cells were harvested by centrifugation at 180 x g for 20 min at 4°C. The cellular pellet was resuspended in 10 ml of 20 mM MOPS buffer (pH 6.8) followed by dilution in one volume of trichlorofluoromethane (Sigma). The sample was vortexed for 1 min and centrifuged at 4,500 x g for 5 min at 4°C. The aqueous phase was transferred to a new tube and this step repeated twice. The sample was then ultracentrifuged at 100,000 x g with a Beckman SW70.2 rotor for 3 h at 4°C. The pellet was resuspended in 3 ml of 50 mM Tris-HCl, pH 8.0, 150 mM CaCl_2, 200 mM NaCl to promote formation of VP6 isolated trimers. Trimeric VP6 was further purified by size exclusion chromatography (Superdex200 16/60 equipped on an AKTA system) and stored at 4 °C.

Transmission electron microscopy. For detection of viroplasms, MA104 cells were seeded at 1x10^5 cells in a 2 cm^2 well onto sapphire discs and infected with OSU [MOI: 100 VFU/cell] (17). At 1 hpi, 20 µM ML was added. At 6 hpi, cells were fixed with 2.5% glutaraldehyde in 100 mM Na/K-phosphate buffer, pH 7.4 for 1 h at 4°C and kept in 100 mM Na/K-phosphate buffer overnight at 4°C. Afterwards, samples were post-fixed in 1% osmium tetroxide in 100 mM Na/K-phosphate buffer for 1 h at 4°C, dehydrated in a graded ethanol series starting at 70% followed by two changes in acetone and embedded in epon. Ultrathin sections (60-80 nm) were cut, stained with uranyl acetate and lead citrate. For EM analyses of purified DLPs incubated with ML for 4 h at 42°C (in the same buffer used in in vitro transcription assays), DLPs were adsorbed for 10 min on glow-discharged carbon-coated Parlodion films mounted on 300 mesh per inch copper grids (EMS). Samples were washed once with distilled water.
and stained with saturated uranyl acetate (Fluka) for 1 min at RT. Samples were analyzed in a transmission electron microscope (CM12, Philips, Eindhoven, The Netherlands) equipped with a CCD camera (Ultrascan 1000, Gatan, Pleasanton, CA, USA) at an acceleration of 100 kV. For negative staining EM experiments of purified VP6, aliquots of trimeric VP6 (0.5 mg/ml) were dialyzed overnight at 4°C against either 50 mM MOPS, pH 6.0, 50 mM NaCl or 50 mM sodium acetate, pH 4.0 to reconstitute VP6 nanotubes and spheres, respectively. After dialysis, VP6 samples were recovered and incubated in the presence or absence of 25 µM ML for 4 h at 37°C (1% DMSO in both conditions). Prior to sample application, the 400-mesh copper carbon-coated grids (Agar Scientific) were glow-discharged for 30 sec at 30 mA using a GloQube system (Quorum Technologies). A 4-µl drop of the incubated VP6 samples at a final concentration of 0.25 mg/ml was applied to the glow-discharged grid and incubated for 1 min. The grid was immediately stained by gentle stirring for 1 min using 2% (w/v) uranyl acetate solution. After staining, the grid was blotted dry and imaged on a Tecnai G2 T20 LaB6 transmission electron microscope (FEI) operating at 200 KeV. Images were manually acquired on an Eagle 2K CCD camera (FEI) at a nominal magnification of 50,000× (corresponding to a pixel size of 4.55 Å at the specimen level) and defocus values in the range of 1.5 µm to 2.5 µm.

Microscale thermophoresis. Thermophoresis was used to determine the binding affinities between recombinant purified VP6 and ML. Experiments were performed in standard capillaries using a Monolith™ NT.115 instrument (NanoTemper Technologies). Either cysteines or lysines of VP6 were labeled with maleimide or NHS dye, respectively, following the manufacturer protocol. Labeled VP6 (100 nM) was incubated at 37 °C for 4 h with increasing concentration of ML (0 to 10^6 nM) in MST buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM MgCl2, 0.05% Tween-20) supplemented with 10% DMSO. Thereafter,
measurements were performed at 24 °C using 20% LED power and 20% MST power. The addition of ML causes quenching of the fluorescent protein due to specific binding, as assessed by the SD-test; therefore, initial fluorescence was used to calculate the affinity. Data were analyzed according to the Hill model (cooperative binding) using the NanoTemper software. Reported affinity value is the average of three independent experiments.

ACKNOWLEDGMENTS

We are grateful to Didier Poncet (Institut de Biologie Intégrative de la Cellule, UMR CNRS, CEA, Univ. PARIS XI, Paris, France) for providing us with BacVP6C; to Bernard Moss (National Institutes of Health, Bethesda, MD, USA) for the pVOTE.1 plasmid and the vvT7/LacOl virus; to Davide Agnello and Pierre Pothier (CNR des virus des gastroentérites, CHU de Dijon, Dijon, France) for the mouse anti-VP6 (clone RV138) monoclonal antibody, and to Jose Luis Zambrano and Ferdinando Liprandi (Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela) for providing us with the mouse anti-VP6 (clone 4B2D2) monoclonal antibody; to Susana López (Instituto de Biotecnología, UNAM, Cuernavaca, Mexico) for the rabbit anti-NSP3 antibody; to Daniel Luque (Centro Nacional de Microbiología, ISICIII, Madrid, Spain) for the rabbit anti-NSP4 antibody and to Harry Greenberg (Stanford University, CA, USA) for the mouse anti-VP5 monoclonal antibody (clone 2G4). We would like to thank Peter Wild for his advice and critical reading.

Most experiments of this study and the work by FA and MB were supported by a FIRB-Futuro in Ricerca grant (RBFR13209E) funded by the Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR), Italy. Also, this work was supported by a private donation of the late Prof Dr. Robert Wyler to MA (F-52601-10-01) as well as by general funds allocated to MA by the University of Zurich. GDL and GP were supported by an ICGEB pre-doctoral fellowship.
The work by MDR, EM, and MM was supported by PRIN 2012 NOXSS (X-ray Single Shots of Nano-Objects), MIUR prot. 2012Z3N9R9.

REFERENCES


Gray J, Desselberger U (ed), Rotaviruses methods and Protocols. Humana Press,
Totowa, New Jersey.

virus-encoded bacteriophage T7 RNA polymerase in mammalian cells. Importance of

42. Ward GA, Stover CK, Moss B, Fuerst TR. 1995. Stringent chemical and thermal
regulation of recombinant gene expression by vaccinia virus vectors in mammalian


protein VP6 of group C rotavirus and synthesis of chimeric single-shelled particles by

45. De Lorenzo G, Eichwald C, Schraner EM, Nicolin V, Bortul R, Mano M, Burrone OR,
93:1474-1482.

46. Gonzalez SA, Burrone OR. 1991. Rotavirus NS26 is modified by addition of single O-
linked residues of N-acetylglucosamine. Virology 182:8-16.

Localization of group-specific epitopes on the major capsid protein of group A

substrate and activation functions of rotavirus NSP5: phosphorylation of Ser-67 by


**FIGURE LEGENDS**

**Fig. 1. ML effect on RV replication.** (A-E) Western blot and confocal immunofluorescence analysis with the indicated antibodies of RV-infected cells (MOI, 25 VFU/cell) treated with ML at 10 μM, unless otherwise indicated, or DMSO (D) for the indicated time windows. Scale bars, 10 μm. (F) Time course of viral progeny yield of OSU-infected (MOI, 25 VFU/cell) MA104 cells treated with 10 μM ML, added at 2 hpi. Data are presented as average ± standard deviation of three independent experiments. t-Test, (***p<0.001. (G) Genome segments analysis of blotted total RNA extracted from non-infected (NI) and OSU-infected MA104 cells (25 VFU/cell) treated with ML (10 μM) or DMSO from 1 to 8 hpi and revealed with an anti-dsRNA antibody. (H) Viability of non-infected or OSU-infected (MOI, 25 VFU/cell) MA104 cells determined by cytofluorometry of propidium iodide stained cells following treatment at 2 hpi with or without 10 μM ML for up to 12 hpi. Data are presented as average ± standard deviation of three independent experiments. T-test, (*)p<0.05; (**) p<0.01 and (***) p<0.001.
**Fig. 2.** Electron microscopy of RV-infected cells treated with ML. High-definition electron microscopy of non-infected (NI) and RV-infected (OSU; MOI, 100 VFU/ml) MA104 cells untreated (DMSO) or treated with ML (20 µM) from 1 hpi. At 6 hpi, cells were fixed with glutaraldehyde and processed for transmission electron microscopy. V, viroplasms; Nu, nucleus, ER, endoplasmic reticulum; Gg, Golgi complex; Vc, vacuoles; P, phagosomes; CM, cell membrane; thin white arrows indicate the endoplasmic reticulum membrane surrounding viroplasms; solid white arrowheads indicate viral particles. The corresponding scale bars are shown in each image.

**Fig. 3.** NSP5 dephosphorylation caused by ML-mediated viroplasm disruption. Western blot and confocal immunofluorescence analysis with the indicated antibodies of OSU-infected MA104 cells (25 VFU/cell) treated with 10 µM ML and/or 0.5 µM okadaic acid (OA) or DMSO for the indicated time windows. Scale bars, 5 µm.

**Fig. 4.** ML antiviral activity is independent of cellular transcription and protein synthesis. (A) Western blot and confocal immunofluorescence analysis with the indicated antibodies of OSU-infected MA104 cells (25 VFU/cell) fed with ethynyl uridine (EU) and treated with 10 µM ML and/or 10 µg/ml actinomycin D or DMSO for the indicated time windows. EU-labeled, newly synthesized RNAs were visualized by reaction with an Alexa-488 conjugated azide (green). Scale bars, 5 µm. (B) Western blot and confocal immunofluorescence with the indicated antibodies of OSU-infected (MOI, 25 VFU/cell) MA104 cells treated with 10 µM ML and/or 10 µg/ml cycloheximide (CHX) or DMSO for the indicated time windows. Scale bars, 10 µm.

**Fig. 5.** ML-mediated impairment of DLP stability. (A) Transcriptional activity of purified DLPs. The plot shows the dose-dependent decrease of transcripts produced by SA11 or OSU DLPs incubated in the presence of the indicated concentrations of ML. The small molecule ID
#7749832 (ChemBridge Corp.) at 200 μM was used as an irrelevant compound (irr.). The data represent the mean ± standard deviation of at least three independent experiments. t-Test, (**)p<0.01, (***)p<0.001 and ns, p>0.01. (B-C) DLPs morphology analyzed by electron microscopy. Purified DLPs were incubated for 4 h with the indicated concentrations of ML or DMSO. Open white arrows indicate damaged DLPs with an irregular shape and partially open. Quantification of damaged DLPs is shown in C. The data in graph C are presented as average ± SEM; t-test (*** p<0.001; n>100.

Fig. 6. Effect of ML on RV VP6. (A) VP6-VP2 interaction. Western blot analysis with anti-VP2 and anti-VP6 antibodies of immunoprecipitates (IP) obtained with anti-VP6 mAb RV138 from extracts of MA104 cells transfected with VP6 and VP2 and treated for 5 h with 10 μM ML or DMSO. The inhibitor (200 μM) was maintained during cell lysis and incubation with the precipitating antibody. (B) VP6 trimer stability. Left panel: Western blot analysis with anti-VP6 antibody of non-boiled extracts from MA104 cells infected with a recombinant vaccinia virus expressing VP6 (vvVP6) and treated with 10 μM ML or DMSO from 1 to 7 hpi. Right panel: Western blot analysis of non-boiled extracts from cells infected with OSU (MOI, 25 VFU/cell) treated with 10 μM ML or DMSO from 1 to 5 hpi. (C) Confocal immunofluorescence analysis with the anti-VP6 mAb 4B2D2 of MA104 cells overexpressing VP6 (infected with vvVP6) and treated with 10 μM ML or DMSO from 1 to 7 hpi. The white arrow indicates a VP6 higher order structure observed in the absence of other RV proteins. Scale bars, 5 μm. (D) Representative images of VP6 tubes and spheres visualized by negative staining electron microscopy after treatment with 25 μM ML for 4 h at 37˚C. Scale bar, 100 nm. (E) Interaction of VP6 with ML evaluated by nanoscale thermophoresis. The fraction of Cys- or Lys-labeled VP6 bound to ML was plotted against increasing concentrations of the inhibitor. Data were
fitted with two state equations and an EC\textsubscript{50} of 294 ± 62 µM calculated as the average of three independent measurements.

**Fig. 7. ML effect on VLS.** Confocal immunofluorescence of VLS (A, C) and Western blot analysis (B) with the indicated antibodies of MA104 cells transfected with NSP5, NSP2, VP2 and VP6, as indicated. In (A) NSP5 is shown in green and NSP2 or VP2 in red. In (C) NSP5 is shown in red, and VP6 in green. Cells were treated for 5 h with 10 µM ML or DMSO at 18 h post-transfection.

**Fig. 8. VP6 in RV-infected cells.** Confocal immunofluorescence of MA104 cells infected with either OSU or SA11 (MOI, 25 VFU/cell) and: A) transfected with siRNAs specific for SA11 VP6 or OSU VP6, or with a non-targeting siRNA (siNT); B) treated with 10 µM ML or DMSO. At the times points post-infection indicated viroplasms were visualized with anti-NSP5 antibody (red) and VP6 with mAb 4B2D2 (green). Scale bars, 5 µm.